Modalis Therapeutics Corp. engages in the development of gene therapy drugs. It uses CRISPR-GNDM, a gene modulation technology that assists patients fighting with genetic disorders. The company was founded by Haruhiko Morita and Osamu Nureki in January 2016 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company